Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamorolone Long-term Extension in DMD
NCT03038399Phase 2Completed
- Sponsor
- ReveraGen BioPharma
- Start
- Feb 2017
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of vamorolone in Duchenne muscular dystrophy (DMD), sponsored by ReveraGen BioPharma. Started Feb 2017; status: completed.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03038399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038399.